Coronavirus / COVID

The strategies address booster doses, travel, and rapid response.

The first Omicron COVID-19 case was discovered in California. The patient, who traveled from South Africa, has since recovered.

If the FDA authorizes molnupiravir based on the Antimicrobial Drugs Advisory Committee's recomendation, it would become the first oral COVID-19 treatment.

A recent study attributed COVID-19 morbidity and mortality disparities to “upstream issues” such as underlying conditions and lack of access to testing and care.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.

Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.

While there is much still unknown about the Omicron variant, the World Health Organization says it poses “very high” risk due to its increased transmissibility.

Inhaled ciclesonide did not shorten duration of mild to moderate symptoms of COVID-19 in outpatients, but lessened hospitalizations.

The strain identified as B.1.1.529 is causing some travel restrictions from some African countries, and medical science is rushing to understand its potential impact on the global stage.

COVID-19 vaccines are frequently tested in low- and middle-income countries, but they have experienced significant delays in vaccinating their own populations.

COVID-19 infection during pregnancy induced immune system rewiring in both mothers and their infants.

In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.

The European Center for Diseases Prevention and Control published data today showing the greatest decrease in antibiotic consumption in 2 decades coincided with the COVID-19 pandemic.

AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.

Retesting positive COVID-19 PCR tests from asymptomatic, nonexposed persons and tests stored next to a specimen with high viral load identified false positives.

A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.

Investigators analyzed data from COVID-NET across 14 states as this variant quickly become the dominant strain within the United States.

Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.

This agreement with the Medicines Patient Pool (MPP) would allow licensing of the company’s antiviral treatment candidate, PF-07321332, internationally to numerous countries.

Just 39 cases among more than 2.2 million doses administered.

A recent study supported the use of a therapeutic dose of heparin for moderately ill patients with COVID-19, with results showing a significant reduction in all-cause death despite no significant reduction in a composite of death, mechanical ventilation and ICU admission.

2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.

A multicenter, randomized trial of patients in Europe and India showed improvements in mortality among patients with COVID-19 who received a higher dose of dexamethasone.

COVID-19 testing has been an integral part of our country’s strategy to limit disease transmission. Here’s the latest information on types of tests, when they’re appropriate to use, and what they realistically can and cannot do to curb infection.

Pfizer-BioNTech's request for the Emergency Use Authorization (EUA) will apply to everyone 18 years and older.

A new study looks at this population and what factors affect outcomes, including diagnosis. This is significant not only for pandemic response, but also preparedness for vulnerable patient populations.

This morning, Regeneron released their phase 3 trail data for REGEN-COV, showing 4 injections provide up to 81.6% protection against symptomatic COVID-19.

A survey published in JAMA reveals some remain firmly entrenched.